Moderna Expected To Soar After Receiving $472 Million Support

On Friday Moderna (NASDAQ: MRNA) fell 2.81% to $73.21 on 27,797,477 shares. Last week was bad for Moderna’s stock movement from $94.99 by facing a $21.78 loss.

Sunday’s good news regarding funds that came from the Federal government to speed up the development of the COVID-19 vaccine could actually push MRNA higher next week. PErhaps, Monday may show rocketing prices for MRNA which can make many investors buy a lot of shares so they can make quick gains.

Other participating biotech companies in COVID-19 vaccine development may receive some funds from governments amid the negative impact of the pandemic. Maybe, Vaxart and Pfizer will get significant financial aids soon. Adding them to the watchlist may lead to huge margins.